JP2009292810A5 - - Google Patents

Download PDF

Info

Publication number
JP2009292810A5
JP2009292810A5 JP2009104886A JP2009104886A JP2009292810A5 JP 2009292810 A5 JP2009292810 A5 JP 2009292810A5 JP 2009104886 A JP2009104886 A JP 2009104886A JP 2009104886 A JP2009104886 A JP 2009104886A JP 2009292810 A5 JP2009292810 A5 JP 2009292810A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peptide
seq
composition according
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009104886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009292810A (ja
JP5717268B2 (ja
Filing date
Publication date
Priority claimed from EP08008292A external-priority patent/EP2113253B1/en
Application filed filed Critical
Publication of JP2009292810A publication Critical patent/JP2009292810A/ja
Publication of JP2009292810A5 publication Critical patent/JP2009292810A5/ja
Application granted granted Critical
Publication of JP5717268B2 publication Critical patent/JP5717268B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009104886A 2008-04-24 2009-04-23 ワクチン用のヒト白血球抗原(hla)クラスiまたはii分子に結合する腫瘍関連ペプチドの新規組成物 Active JP5717268B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4766908P 2008-04-24 2008-04-24
US61/047,669 2008-04-24
EP08008292A EP2113253B1 (en) 2008-04-30 2008-04-30 Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
EP08008292.8 2008-04-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012200596A Division JP5921395B2 (ja) 2008-04-24 2012-09-12 ワクチン用のヒト白血球抗原(hla)クラスiまたはii分子に結合する腫瘍関連ペプチドの新規組成物

Publications (3)

Publication Number Publication Date
JP2009292810A JP2009292810A (ja) 2009-12-17
JP2009292810A5 true JP2009292810A5 (https=) 2012-01-26
JP5717268B2 JP5717268B2 (ja) 2015-05-13

Family

ID=39643855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009104886A Active JP5717268B2 (ja) 2008-04-24 2009-04-23 ワクチン用のヒト白血球抗原(hla)クラスiまたはii分子に結合する腫瘍関連ペプチドの新規組成物

Country Status (20)

Country Link
US (2) US9289478B2 (https=)
EP (2) EP2113253B1 (https=)
JP (1) JP5717268B2 (https=)
CN (1) CN105749285A (https=)
AT (2) ATE462442T1 (https=)
AU (1) AU2009201589C1 (https=)
BR (1) BRPI0900798A8 (https=)
CA (1) CA2665510C (https=)
CY (1) CY1110178T1 (https=)
DE (1) DE602008000891D1 (https=)
DK (2) DK2113253T3 (https=)
EA (1) EA017492B1 (https=)
ES (2) ES2342506T3 (https=)
HR (2) HRP20100354T1 (https=)
MX (1) MX2009004468A (https=)
NZ (1) NZ576423A (https=)
PL (2) PL2113253T3 (https=)
PT (2) PT2113253E (https=)
RS (1) RS52115B (https=)
SI (2) SI2113253T1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2006023598A2 (en) 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2012079878A2 (en) * 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
BRPI0813621A2 (pt) 2007-07-27 2017-05-09 Immatics Biotechnologies Gmbh imunoterapia contra tumores neuronais e cerebrais
PL2565204T3 (pl) 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
WO2010098788A2 (en) * 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2014271235B2 (en) * 2008-10-01 2017-03-02 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
AU2016204708B2 (en) * 2008-10-01 2018-02-22 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2013041542A1 (en) * 2011-09-19 2013-03-28 Alf Lamprecht Pharmaceutical formulations comprising spherolyophilisates of biological molecules
SG11201405578TA (en) 2012-03-09 2014-11-27 Oncotherapy Science Inc Pharmaceutical composition containing peptide
CN110123763A (zh) 2012-06-21 2019-08-16 法斯瑞斯公司 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法
TWI775117B (zh) 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(二)
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
ES2983924T3 (es) * 2015-03-27 2024-10-28 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EA201792531A1 (ru) * 2015-06-19 2018-05-31 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака
CA2936070C (en) * 2015-07-14 2023-07-04 Professional Compounding Centers Of America (Pcca) Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
IL299051A (en) * 2017-01-27 2023-02-01 Immatics Biotechnologies Gmbh New peptides and their combinations for immunotherapy against ovarian cancer and other cancers
MA47367B1 (fr) * 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
EP4149512A4 (en) * 2020-05-12 2024-06-05 Board of Regents, The University of Texas System Methods for treating glioblastoma
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
WO2023148333A1 (en) 2022-02-03 2023-08-10 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
EP4410767B1 (de) 2023-02-03 2025-10-01 Röhm GmbH Nachhaltiges c3 verfahren mit integrierter erzeugung von rohstoffen

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045796A (en) * 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
HK1046925A1 (zh) * 1999-10-19 2003-01-30 Ludwig Institute For Cancer Research Mage-a12抗原肽及其用途
US6897288B1 (en) * 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
PT1517698E (pt) * 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
KR20050121721A (ko) * 2003-04-11 2005-12-27 안티제닉스 아이엔씨 개량된 열 충격 단백질 기초 백신 및 면역치료법
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
CN112618700A (zh) * 2004-11-12 2021-04-09 诺和诺德公司 促胰岛素肽的稳定制剂
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
ES2367643T3 (es) * 2005-04-26 2011-11-07 Immatics Biotechnologies Gmbh Identificador de un epítopo de linfocitos t presentado por el antígeno hla-a2 y derivado de la proteína del receptor de laminina inmadura del antígeno oncofetal y usos de este.
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
PL1760089T3 (pl) 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
WO2007028753A2 (de) 2005-09-09 2007-03-15 Basf Aktiengesellschaft Fungizide mischungen auf der basis von triazolen
WO2007146668A2 (en) * 2006-06-06 2007-12-21 University Of Massachusetts Use of imp3 as a prognostic marker for cancer
SI2119726T2 (en) * 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka

Similar Documents

Publication Publication Date Title
JP2009292810A5 (https=)
ES2342506T3 (es) Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
JP2010500399A5 (https=)
JP2008530245A5 (https=)
JP2020023567A5 (https=)
CN109219448B (zh) Hiv疫苗配制品
JP2010515686A5 (https=)
Xiao et al. Therapeutic effects of neuregulin-1 gene transduction in rats with myocardial infarction
JP2011520783A5 (https=)
JP2015530404A5 (https=)
JP2016512213A5 (https=)
JP2013515057A5 (https=)
JP2011524420A5 (https=)
JP6825181B2 (ja) 膵炎を治療するための薬剤の製造におけるil−22二量体の使用
JP2013504589A5 (https=)
JP2012521201A5 (https=)
JP2010202664A5 (https=)
JP2016520075A5 (https=)
US20210393769A1 (en) Coronavirus vaccine and methods of use thereof
JP2008530975A5 (https=)
JP2014508734A5 (https=)
US20160158374A1 (en) Cell-penetrating peptide and conjugate comprising same
JP2019534884A5 (https=)
JP2010523564A (ja) 抗ウイルス性ペプチド治療薬の送達のための新規製剤
JP2012102105A5 (https=)